Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1/2 TAK-981 plus rituximab in relapsed/refractory CD20-positive non-Hodgkin lymphoma
jRCT2031210060Phase 2Completed
- Sponsor
- Takeda
- Start
- Oct 2019
- Modality
- Small Molecules
01
Overview
Phase 2, open-label trial of subasumstat in non-Hodgkin lymphoma (NHL), diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL) and 2 more (9 arms), sponsored by Takeda. Started Oct 2019; status: completed.
02
Drugs
subasumstat
03
Conditions
non-Hodgkin lymphoma (NHL)diffuse large B-cell lymphoma (DLBCL)follicular lymphoma (FL)mantle cell lymphoma (MCL)marginal zone B-cell lymphoma (MZL)
Beyond the preview
Go deeper on jRCT2031210060.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031210060.